PDF ↗
Dart ConsultantsDart HomeAI Compute StackDC Physical InfrastructureUnified: Wafer to SubstationAerospace ManufacturingPharma Excipients & Cellulosics
Research Primer · Dart Consultants

Pharmaceutical Excipients & Cellulosics

A ground-up guide — from the physics of a compressed tablet to the two listed Indian companies supplying the world's formulation industry from Gujarat and Telangana.

Primer sections11
Companies2
Value-chain steps4
Ratings1H·1S
  • 1Active ingredient (API)The molecule that treats the patient — often 5–30% of tablet mass, sometimes under 1%
  • 2Filler / diluent — MCCGives the tablet its bulk and, critically, its compressibility — the largest single component by weight
  • 3Disintegrant — CCS, SSGSwells on contact with water and breaks the compact apart so the dose can dissolve
  • 4Lubricant & glidantMagnesium stearate, colloidal silica — lets powder flow into the die and the tablet eject cleanly
  • 5BinderHolds the granule together before compression — HPMC, povidone, or MCC doing double duty
  • 6Film coatTaste masking, moisture barrier, and — for modified release — the rate-controlling layer

The molecule is the easy part. The particle is the product.

The Primer

11 sections, read start to finish or jump to any one
Orientation

How to read this report

This is a first-principles primer built around one physical contrast: making cellulose is a scaling problem; shaping the particle precisely is a control problem. Hold that…

Read →
Section 1

The vocabulary

Three words — API, excipient, formulation — decide almost everything about who can compete where in this industry, and what they are allowed to earn for it.…

Read →
Section 2

The science: two problems

A tablet must survive being made and must release its dose for years — two opposite physical problems, tuned by different levers, that fail in completely different ways.…

Read →
Section 3

Why the particle is the hard problem

The chemistry is seventy years old and unpatented. What is scarce, and what the money sits on, is reproducing a particle-size distribution batch after batch.…

Read →
Section 4

Granulation vs direct compression

If particle engineering is so valuable, why does anyone still buy the cheap grades? Because for most of pharmaceutical history, the formulator did it themselves, for free.…

Read →
Section 5

Grade classes & the value ladder

Two naming systems get mixed together in this industry. Untangled, they reveal the sector's central fact: difficulty, barriers and margin all climb the same ladder.…

Read →
Section 6

The industry & its demand drivers

Five concurrent demand cycles run at once, so no single end-market slowdown derails the thesis — and published market-size estimates disagree by a third.…

Read →
Section 7

Regulation & the qualification clock

An excipient has no independent regulatory approval of its own. Qualifying a new source into an approved product typically takes three to five years — that is the moat.…

Read →
Section 8

The parts the data misses

Trading volume, co-processed systems and the food/nutraceutical spillover are all structurally undercounted by headline market figures — and all push toward the premium end.…

Read →
Section 9

The companies

India has two listed cellulosic pure-plays — Accent Microcell and Sigachi Industries — that began from a similar place and took visibly different paths.…

Read →
Section 10

Synthesis

The producers in this sector are all doing one of four things, and the whole industry is migrating in one direction along the grade ladder.…

Read →
Section 11

Stock ratings summary

Ratings key and comparative table, used consistently across both company reports in this document.…

Read →
Notes

Methodology & disclaimer

This primer follows Dart Consultants' standard first-principles method, synthesising public company disclosures, credit-rating publications and industry-association guidance.…

Read →

The Two Companies

0 BUY · 1 HOLD · 1 SELL
HOLDACCENTMIC

Accent Microcell

Quality is not in question; the price already pays for the plant

Target Rs 730 · CMP Rs 697 · +5%
SELLSIGACHI

Sigachi Industries

A guided recovery, a discounted dilution and an unresolved legal file

Target Rs 31 · CMP Rs 37.6 · (18%)
Educational material only — not investment advice.Dart Consultants is not a SEBI-registered Investment Adviser or Research Analyst.